System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Gilbert Habib is an expert in Cardiology at Hôpital de la Timone (France). As of October 2026, ScienceLeadR ranks Gilbert Habib in the top 1% of experts worldwide for Endocarditis, Cardiomyopathies and Aortic Valve Disease. Gilbert Habib has authored 690 publications, the most recent in 2026, and is an investigator in 28 clinical trials, 10 of them ongoing. SLR score: 2,458 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Gilbert Habib Hôpital de la Timone France
2 458 ScienceLeadR Reputation 2458

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Public Health - Nuclear Medicine - Medical Imaging

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1991 - 2026
Source: PubMed

Hôpital de la Timone

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 690

Citations

Citations: 72 798 1st author: 32 Last author: 159 Unique author: 17

Main journals

Eur Heart J 72
Eur Heart J Cardiovasc Imaging 64
Arch Cardiovasc Dis 41
Archives of Cardiovascular Diseases Supplements 31
J Am Coll Cardiol 26

Best Journals

Eur Heart J 27
N Engl J Med 7
Circulation 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Duration of antibiotic treatment for infective endocarditis: should we move towards tailored therapy?
PMID 42881212 — cardiovascular diseases, endocarditis, therapeutics		Nat Rev Cardiol Top journal20260
Rivaroxaban for Stroke Prevention in Hypertrophic Cardiomyopathy Without Atrial Fibrillation and With Impaired Left Atrial Reservoir Strain: Design and Rationale of the LA-HCM Randomized Trial.
PMID 42844166 — stroke, rivaroxaban, atrial fibrillation, cardiomyopathy, hypertrophic, cardiomyopathies		Eur Heart J Cardiovasc Imaging20260
Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
PMID 42667274 — cardiomyopathy, hypertrophic, therapeutics, blood circulation, cardiomyopathies		Circulation Top journal20261
Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM.
PMID 42663111 — exercise, heart failure, diastolic, cardiomyopathy, hypertrophic, cardiac myosins, therapeutics, blood circulation, cardiomyopathies		Circulation Top journal20261
Sex Differences in Phenotype and Tafamidis-Associated Survival in Val122Ile Transthyretin Cardiac Amyloidosis.
PMID 42506952 — heart failure, phenotype, prealbumin, amyloidosis, sex characteristics, sex, transthyretin amyloidosis, transthyretin cardiac amyloidosis, sex differences		JACC Heart Fail20260

Clinical Studies 28

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 13
Phase 3 12
Phase 2 1
Phase 2/Phase 3 1
Phase 3/Phase 4 1

By status:

Completed 11
Active not recruiting 5
Unknown 5
Recruiting 4
Enrolling by invitation 2
Not yet recruiting 1

By type:

Interventional 21
Observational 7

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 0
multicentric5to9 1
multicentricup10 21

Main Topics

Cohort/Consortium Investigators 19

Ongoing Clinical Trials

10 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
CLEOPATTRA A research study to look at the effects of treatment with a medicine called coramitug (NNC6019 0001) in people with heart failure due to ATTR amyloidosis
2024-518899-31-00 — heart failure, heart, prealbumin, amyloidosis, research, therapeutics, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis		Phase 3Recruiting2025
A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
2024-518343-38-00 — safety, prealbumin, amyloidosis, therapeutics, cardiomyopathies, transthyretin amyloidosis		Phase 3Active not recruiting2025
A study to determine if ALXN2220 is effective safe and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR CM)
2023-506669-70-00 — safety, prealbumin, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis		Phase 3Active not recruiting2024
TRITON CM A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
2024-519917-72-00 — safety, prealbumin, amyloidosis, therapeutics, cardiomyopathies, transthyretin amyloidosis		Phase 3Not yet recruiting2025
LA HCM Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients with Abnormal Left Atrial Strain A Randomized Multicenter Trial
2024-511084-28-00 — rivaroxaban, cardiomyopathy, hypertrophic, cardiomyopathies		Phase 3/Phase 4Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS